3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Sell
43
GMRE Quote, Financials, Valuation and Earnings
Last price:
$8.79
Seasonality move
:
7.98%
Day range:
$8.72 - $8.88
52-week range:
$7.33 - $10.46
Dividend yield:
9.6%
P/E ratio:
875.00x
P/S ratio:
4.17x
P/B ratio:
1.27x
Volume:
430.9K
Avg. volume:
498.4K
1-year change:
--
Market cap:
$585.1M
Revenue:
$138.4M
EPS (TTM):
$0.01
Analysts' Opinion
-
Consensus RatingGlobal Medical REIT has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 4 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.68, Global Medical REIT has an estimated upside of 22.04% from its current price of $8.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.50 representing 100% downside risk from its current price of $8.75.
Fair Value
-
According to the consensus of 8 analysts, Global Medical REIT has 22.04% upside to fair value with a price target of $10.68 per share.
GMRE vs. S&P 500
-
Over the past 5 trading days, Global Medical REIT has overperformed the S&P 500 by 5.53% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Global Medical REIT does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Global Medical REIT has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Global Medical REIT reported revenues of $35M.
Earnings Growth
-
Global Medical REIT earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Global Medical REIT reported earnings per share of $0.02.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
4.17x
EV / EBIT:
37.34x
EV / Revenue:
9.55x
PEG ratio (5yr expected):
1.00x
EV / Free cash flow:
-52.69x
Price / Operating cash flow:
24.65x
Enterprise value / EBITDA:
14.44x
Gross Profit (TTM):
$109.2M
Return On Assets:
0.53%
Net Income Margin (TTM):
4.79%
Return On Equity:
1.14%
Return On Invested Capital:
0.55%
Operating Margin:
18.34%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $137.2M | $140.9M | $138.4M | $32.9M | $35M | |
| Gross Profit | $112M | $112.9M | $109.2M | $26.8M | $27.8M | |
| Operating Income | $38.7M | $37.9M | $32.7M | $8.4M | $6.4M | |
| EBITDA | $102.9M | $111.6M | $91.5M | $22M | $24.4M | |
| Diluted EPS | $0.20 | $0.23 | $0.01 | -$0.01 | $0.02 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21.3M | $24.9M | $30.5M | $14.4M | $17.3M | |
| Total Assets | $1.1B | $1.3B | $1.4B | $1.3B | $1.3B | |
| Current Liabilities | $541.4M | $540.6M | $670.5M | $619.3M | $671.5M | |
| Total Liabilities | $643.1M | $625.9M | $744.2M | $661.9M | $700.6M | |
| Total Equity | $457.8M | $637.6M | $649.1M | $605.8M | $555.9M | |
| Total Debt | $586.6M | $571.7M | $694.1M | $611.2M | $646.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $76.5M | $68.4M | $70M | $18.1M | $20.5M | |
| Cash From Investing | -$137.3M | $67.6M | -$45.9M | -$3.1M | -$19.5M | |
| Cash From Financing | $62.4M | -$143.8M | -$21.9M | -$15.9M | $153K | |
| Free Cash Flow | -$79.7M | $58.4M | -$25.1M | $14.3M | -$33.3M | |
GMRE
Sector
Market Cap
$585.1M
$1B
Price % of 52-Week High
83.65%
80.89%
Dividend Yield
9.6%
3.28%
Shareholder Yield
--
3.41%
1-Year Price Total Return
--
-2.15%
Beta (5-Year)
1.120
0.770
Dividend yield:
9.6%
Annualized payout:
$0.84
Payout ratio:
990.35%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.57
200-day SMA
Sell
Level
$8.87
Bollinger Bands (100)
Buy
Level
7.92 - 8.82
Chaikin Money Flow
Sell
Level
-13.4M
20-day SMA
Buy
Level
$8.72
Relative Strength Index (RSI14)
Buy
Level
56.89
ADX Line
Buy
Level
18.9
Williams %R
Neutral
Level
-29.0323
50-day SMA
Buy
Level
$8.35
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-14.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.2426)
Sell
CA Score
(Annual)
Level (-0.559)
Buy
Beneish M-Score
(Annual)
Level (-2.6831)
Sell
Momentum Score
Level (3)
Sell
Ohlson Score
Level (5.5135)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.
Stock Forecast FAQ
In the current month, GMRE has received 4 Buy ratings 4 Hold ratings, and 0 Sell ratings. The GMRE average analyst price target in the past 3 months is $10.68.
-
Where Will Global Medical REIT Stock Be In 1 Year?
According to analysts, the consensus estimate is that Global Medical REIT share price will rise to $10.68 per share over the next 12 months.
-
What Do Analysts Say About Global Medical REIT?
Analysts are divided on their view about Global Medical REIT share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Global Medical REIT is a Sell and believe this share price will drop from its current level to $9.50.
-
What Is Global Medical REIT's Price Target?
The price target for Global Medical REIT over the next 1-year time period is forecast to be $10.68 according to 8 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is GMRE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Global Medical REIT is a Leans Bullish. 4 of 8 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of GMRE?
You can purchase shares of Global Medical REIT via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Global Medical REIT shares.
-
What Is The Global Medical REIT Share Price Today?
Global Medical REIT was last trading at $8.79 per share. This represents the most recent stock quote for Global Medical REIT. Yesterday, Global Medical REIT closed at $8.75 per share.
-
How To Buy Global Medical REIT Stock Online?
In order to purchase Global Medical REIT stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 15.47% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 3.02% over the past day.
Sell
47
RGC alert for Apr 1
Regencell Bioscience Holdings [RGC] is down 2.32% over the past day.
